Valneva Shares Jump After Early Study Show Covid-19 Vaccine Effective Against Omicron

日本 ニュース ニュース

Valneva Shares Jump After Early Study Show Covid-19 Vaccine Effective Against Omicron
日本 最新ニュース,日本 見出し
  • 📰 Forbes
  • ⏱ Reading Time:
  • 61 sec. here
  • 3 min. at publisher
  • 📊 Quality Score:
  • News: 28%
  • Publisher: 53%

I am a London-based reporter for Forbes covering breaking news. Previously, I have worked as a reporter for a specialist legal publication covering big data and as a freelance journalist and policy analyst covering science, tech and health. I have a master’s degree in Biological Natural Sciences and a master’s degree in the History and Philosophy of Science from the University of Cambridge. Follow me on Twitter @theroberthart or email me at [email protected]

Three doses of Valneva’s Covid-19 vaccine neutralized the omicron coronavirus variant in early laboratory studies, the French biotech

Wednesday, boosting its share price and adding to the stock of vaccines including Pfizer and Moderna that are effective against omicron as it eyes regulatory approval in Europe in the coming months. © 2020 Bloomberg Finance LPThe majority of blood samples from 30 participants in the firm’s clinical trial contained neutralizing antibodies—an indicator of immunity—against omicron, the company said in a statement.

All of the samples had neutralizing antibodies against the original virus strain and the delta variant, Valneva said, though neutralization against delta and omicron was 2.7- and 16.7-fold lower, relative to the original strain. The results complement earlier trials on two doses of the vaccine and demonstrate the shot’s “ability to address currently circulating variants of concern,” said Valneva’s chief medical officer Juan Carlos Jaramillo.Regulatory approval. Valneva expects the shot to receive its first approvals in the first three months of 2022 and the company has been providing data to the European Medicines Agency, the U.K.

a 190 million dose deal with the firm for allegedly breaching supply commitments, something the company strongly denies.

このニュースをすぐに読めるように要約しました。ニュースに興味がある場合は、ここで全文を読むことができます。 続きを読む:

Forbes /  🏆 394. in US

日本 最新ニュース, 日本 見出し

Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。

Bleach Creator Shares Cool New Sketch of IchigoBleach Creator Shares Cool New Sketch of IchigoThe creator of Bleach has shared a cool new sketch of Ichigo, and you can get more through his fan club!
続きを読む »

Lt. governor candidate ends campaign, endorses primary opponent who shares criminal justice reform goalsLt. governor candidate ends campaign, endorses primary opponent who shares criminal justice reform goalsBrandon Flood, the former Board of Pardons secretary, has ended his campaign for the GOP nomination for lieutenant governor and is backing Jeff Coleman in that crowded field of candidates.
続きを読む »

'Cobra Kai' Star Gianni DeCenzo Shares His Version of Demetri's Home Life'Cobra Kai' Star Gianni DeCenzo Shares His Version of Demetri's Home LifeCobra Kai's Gianni DeCenzo explains why Demetri never falls to the dark side and reveals some backstory details he's developed for the character.
続きを読む »

Goldman shares tumble as weak trading, higher pay hit profitGoldman shares tumble as weak trading, higher pay hit profitGoldman Sachs Group missed quarterly profit expectations on Tuesday as weak trading activity and rising expenses blighted the gains from a record-breaking M&A boom, sending the shares of Wall Street's premier investment bank down more than 8%.
続きを読む »



Render Time: 2025-03-06 12:39:52